Announcement

Collapse
No announcement yet.

Infection-competent monkeypox virus contamination identified in domestic settings following an imported case of monkeypox into the UK - Preprint, medRxiv

Collapse
X
Collapse
 
  • Page of 1
  • Filter
  • Time
  • Show
Clear All
new posts
Previous template Next
  • #1

    Infection-competent monkeypox virus contamination identified in domestic settings following an imported case of monkeypox into the UK - Preprint, medRxiv

    This article is a preprint and has not been certified by peer review

    Posted June 27, 2022

    doi: https://doi.org/10.1101/2022.06.27.22276202

    Barry Atkinsona*#, Christopher Burtonb*, Thomas Pottagea, Katy-Anne Thompsona, Didier Ngaboa, Ant Crooka, James Pitmanb, Sian Summersb, Kuiama Lewandowskia, Jenna Furneauxc, Katherine Daviesa, Timothy Brooksc,d, Allan M Bennetta and Kevin S. Richards,b,e

    Abstract

    An imported case of monkeypox was diagnosed in December 2019 in a traveller returning from Nigeria to the UK. Subsequently, environmental sampling was performed at two adjoining single room residences occupied by the patient and their sibling. Monkeypox virus DNA was identified in multiple locations throughout both properties, and monkeypox virus was isolated from several samples three days after the patient was last in these locations. Positive samples were identified following use of both vacuum and surface sampling techniques; these methodologies allowed for environmental analysis of potentially contaminated porous and non-porous surfaces via real-time quantitative PCR analysis in addition to viral isolation to confirm the presence of infection-competent virus.

    This report confirms the potential for infection-competent monkeypox virus to be recovered in environmental settings associated with known positive cases and the necessity for rapid environmental assessment to reduce potential exposure to close contacts and the general public. The methods adopted in this investigation may be used for future confirmed cases of monkeypox in order to establish levels of contamination, confirm the presence of infection-competent material, and to identify locations requiring additional cleaning.

    Infection-competent monkeypox virus contamination identified in domestic settings following an imported case of monkeypox into the UK
    https://www.medrxiv.org/content/10.1101/2022.06.27.22276202v1.full
    An imported case of monkeypox was diagnosed in December 2019 in a traveller returning from Nigeria to the UK. Subsequently, environmental sampling was performed at two adjoining single room residences occupied by the patient and their sibling. Monkeypox virus DNA was identified in multiple locations throughout both properties, and monkeypox virus was isolated from several samples three days after the patient was last in these locations. Positive samples were identified following use of both vacuum and surface sampling techniques; these methodologies allowed for environmental analysis of potentially contaminated porous and non-porous surfaces via real-time quantitative PCR analysis in addition to viral isolation to confirm the presence of infection-competent virus. This report confirms the potential for infection-competent monkeypox virus to be recovered in environmental settings associated with known positive cases and the necessity for rapid environmental assessment to reduce potential exposure to close contacts and the general public. The methods adopted in this investigation may be used for future confirmed cases of monkeypox in order to establish levels of contamination, confirm the presence of infection-competent material, and to identify locations requiring additional cleaning. Originality-Significance Statement Several imported cases of human monkeypox infection, an emerging infectious disease with a case fatality rate of up to 10%, have been identified in recent years including importations into the United Kingdom, the United States, Israel, and Singapore. It is likely that this phenomenon relates to decreased immunity against monkeypox infection in endemic regions that was previously provided via the smallpox vaccination programme. It is therefore likely that further imported cases of monkeypox will be reported in future; such occurrences will require significant clinical oversight, including suitable infection control measures. Environmental sampling to identify contaminated sites that may pose a risk can inform infection control guidance. This report documents an environmental sampling response following an imported case detected in late 2019 in the UK. Monkeypox virus DNA was readily identified in numerous locations throughout two domestic residences associated with the infected patient and infectious virus was isolated from several environmental samples confirming that contaminated environmental settings may pose a risk for onward transmission. The methods utilised in this report may advise future environmental responses following cases of this high consequence emerging viral disease in order to prevent secondary cases in close contacts or members of the public. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was supported by PHE Grant-in-Aid funding. The funding source had no involvement in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The environmental sampling results presented are from an urgent public health investigation performed as part of a UKHSA public health incident response to the importation of a high consequence infectious disease. UKHSA is the national public health agency for England and an executive agency of the UK Government Department of Health. The study protocol was subject to retrospective internal review by the Research Ethics and Governance Group, which is the UKHSA Research Ethics Committee; it was determined that ethical approval was not required. Information pertaining to the clinical case was provided by the Rare and Imported Pathogen Laboratory also located within UKHSA; in the context of communicable diseases, UKHSA has legal permission, provided by Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002, to process confidential patient information with a view to controlling and preventing the spread of such diseases and risks, and monitoring and managing outbreaks of communicable disease. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors

    Tags: None
Previous template Next
Working...
X